Nuveen Asset Management LLC Sells 96,930 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Nuveen Asset Management LLC trimmed its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 61.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 60,401 shares of the company's stock after selling 96,930 shares during the period. Nuveen Asset Management LLC owned about 0.17% of iTeos Therapeutics worth $464,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Virtus ETF Advisers LLC grew its stake in iTeos Therapeutics by 58.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock valued at $69,000 after acquiring an additional 3,293 shares during the period. Forefront Analytics LLC purchased a new stake in iTeos Therapeutics in the 4th quarter valued at $85,000. Graham Capital Management L.P. acquired a new stake in iTeos Therapeutics during the fourth quarter worth about $85,000. SG Americas Securities LLC lifted its holdings in iTeos Therapeutics by 12.2% in the fourth quarter. SG Americas Securities LLC now owns 13,866 shares of the company's stock valued at $106,000 after acquiring an additional 1,508 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of iTeos Therapeutics by 16.9% during the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company's stock worth $128,000 after purchasing an additional 2,402 shares during the last quarter. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

iTeos Therapeutics Price Performance

NASDAQ:ITOS traded down $0.13 during mid-day trading on Monday, reaching $10.04. The company's stock had a trading volume of 1,104,582 shares, compared to its average volume of 661,405. iTeos Therapeutics, Inc. has a twelve month low of $4.80 and a twelve month high of $18.13. The company's fifty day simple moving average is $7.38 and its two-hundred day simple moving average is $7.47. The stock has a market cap of $384.27 million, a P/E ratio of -3.19 and a beta of 1.51.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.14. Sell-side analysts expect that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

Insider Activity at iTeos Therapeutics

In other news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the transaction, the insider now directly owns 3,452,797 shares in the company, valued at $27,829,543.82. The trade was a 23.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Michel Detheux sold 8,400 shares of the company's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $10.21, for a total transaction of $85,764.00. Following the completion of the transaction, the chief executive officer now directly owns 135,903 shares in the company, valued at $1,387,569.63. This trade represents a 5.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,843,142 shares of company stock worth $15,238,020 in the last quarter. 12.50% of the stock is owned by company insiders.

Analyst Ratings Changes

ITOS has been the subject of several research analyst reports. Raymond James set a $12.00 price target on iTeos Therapeutics in a research report on Wednesday, May 14th. Wells Fargo & Company reissued an "equal weight" rating and set a $12.00 target price (down previously from $13.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 28th. Leerink Partnrs cut iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 14th. Wedbush downgraded shares of iTeos Therapeutics from an "outperform" rating to a "neutral" rating and lifted their target price for the company from $10.00 to $12.00 in a report on Wednesday, May 28th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $12.00 price target (down from $16.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $15.86.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.